SeaChange Pharmaceuticals, Inc.

San Jose, CA 95128
http://seachangepharma.com/

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.66MM
First Award Date 06/01/10
Most Recent Award Date 08/01/14

Key Personnel

Last Name Name Awards Contact
Keiser Michael James Keiser 5
Hodge Carl Nicholas Hodge 4

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may be predicted comprehensively and systematically using chemoinformati...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/20/13 - 07/31/14

DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may be predicted comprehensively and systematically using chemoinformati...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 01/18/13 - 01/17/14

DESCRIPTION (provided by applicant): Goals: The goal is to expand the known pharmacological relationships among arrestin and G protein biased ligands. Starting with the Gi-coupled dopamine D2 receptor (D2R), we will predict biased ligands, evaluating our methods both retrospectively and via prospective experimental assay. We then extend this...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/15/11 - 08/31/13

DESCRIPTION (provided by applicant): Goals: The goal is to develop a computational system to predict the targets toward which small molecules are biased. The tool will optimize biased libraries, prioritize them for testing against particular targets, identify targets in phenotypic screens, and allow users to easily move from compounds to targets...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/10 - 05/31/12

DESCRIPTION (provided by applicant): Three ideas motivate this project. First, bioactive small molecules often act on multiple targets- sometimes this "polypharmacology" is key to their efficacy, sometimes it is the source of unwanted side-effects, rarely is it entirely absent. Second, these off-targets may be predicted comprehensively across al...